It contains no other additives no buffers, no antimicrobial agents beyond benzyl alcohol, no tonicity agents
Developing portal hypertension as well as established portal hypertension were both rapidly counteracted in BDL rats (i.e., BPC 157 per-orally, in drinking water, since the end of week 4) (Sever et al., 2019)
It is primarily available for research purposes, and its use in humans carries regulatory and safety considerations
Errors here quietly ruin every subsequent dose
Long-acting formulations extending beyond once-weekly dosing could improve adherence further
Other risk factors include long-term metformin use, vegan diets, and previous gastric or ileal surgery